Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.33 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 2/20 | 0.32 |
| ▸ | BLM | P54132 | 2/20 | 0.31 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.30 |
| ▸ | ALPG | P10696 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Phosphonate SCHEMBL21791 | 0.85 | — | — | |
| Methyl Phosphonate SCHEMBL29461628 | 0.85 | CA2 (1.00) | CA2LMNASLC34A1GABBR2CYP1A2 | |
| Methyl Phosphonate SCHEMBL641732 | 0.84 | CA2 (0.61) | CA2LMNAGABBR2GABBR1GABRR1 | |
| Methyl Phosphonate SCHEMBL9113259 | 0.80 | CA2 (0.89) | CA2LMNASLC34A1GABBR2CYP1A2 | |
| Methyl Phosphonate SCHEMBL4621163 | 0.80 | — | — | |
| Methyl Phosphonate SCHEMBL9706084 | 0.80 | CA2 (0.89) | CA2LMNASLC34A1GABBR2CYP1A2 | |
| Methyl Phosphonate SCHEMBL1303324 | 0.80 | — | — | |
| Methyl Phosphonate SCHEMBL20896851 | 0.80 | CA2 (0.89) | CA2LMNASLC34A1GABBR2CYP1A2 | |
| Methyl Phosphonate SCHEMBL11594170 | 0.80 | — | — | |
| Methyl Phosphonate SCHEMBL17626428 | 0.80 | CA2 (0.89) | CA2LMNASLC34A1GABBR2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2999785-A1 | SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2016-03-30 | — | — | EP | claimed |
| WO-2014190137-A1 | SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-11-27 | — | — | WO | claimed |
| US-20240240182-A1 | HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-07-18 | — | — | US | disclosed |
| EP-4399311-A2 | APP IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING DISEASES CHARACTERIZED BY ENLARGED ENDOSOMES | Alnylam Pharmaceuticals, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-118265786-A | Microtubule-associated protein Tau (MAPT) iRNA pharmaceutical compositions and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20240209373-A1 | ELONGATION OF VERY LONG CHAIN FATTY ACIDS PROTEIN 1 (ELOVL1) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240209339-A1 | REDIRECTING RISC FOR RNA EDITING | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2024129931-A1 | ALPHA-V BETA-6(ανβ6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240200077-A1 | STEAROYL-COA DESATURASE 5 (SCD5) IRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4376953-A1 | PEPTIDE LIGANDS FOR CNS AND OCULAR DELIVERY OF RNAI COMPOUNDS | Alnylam Pharmaceuticals, Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| US-11993774-B2 | Huntingtin (HTT) iRNA agent compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| US-20020182602-A1 | Mobility-modified nucleobase polymers and methods of using same | APPLIED BIOSYSTEMS, INC. | 2002-12-05 | — | — | US | disclosed |
| WO-2002083954-A1 | MOBILITY-MODIFIED NUCLEOBASE POLYMERS AND METHODS OF USING SAME | APPLERA CORPORATION (US) | 2002-10-24 | — | — | WO | disclosed |
| US-6440696-B1 | HUMAN TUMOR SUPPRESSOR PROTEIN IDENTIFIED AS A NOVEL GAP PROTEIN (GTPASE ACTIVATING PROTEIN), DESIGNATED ?E6TP1?; BINDS TO HUMAN PAPILLOMAVIRUS E6 PROTEIN | NEW ENGLAND MEDICAL CENTER | 2002-08-27 | — | — | US | disclosed |
| US-6117992-A | Reagents and process for synthesis of oligonucleotides containing phosphorodithioate internucleoside linkages | HYBRIDON, INC. (US) | 2000-09-12 | — | — | US | disclosed |
| EP-0649467-B1 | SELF-STABILIZED OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS | HYBRIDON INC (US) | 1998-09-16 | — | — | EP | disclosed |
| WO-1998008858-A1 | IMPROVED REAGENTS AND PROCESS FOR SYNTHESIS OF OLIGONUCLEOTIDES CONTAINING PHOSPHORODITHIOATE INTERNUCLEOSIDE LINKAGES | HYBRIDON, INC. (US) | 1998-03-05 | — | — | WO | disclosed |
| WO-1995018137-A1 | IMPROVED PROCESS FOR THE PURIFICATION OF OLIGOMERS | GENTA INCORPORATED (US) | 1995-07-06 | — | — | WO | disclosed |
| EP-0649467-A1 | SELF-STABILIZED OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS | HYBRIDON, Inc. (US) | 1995-04-26 | — | — | EP | disclosed |
| WO-1994001550-A1 | SELF-STABILIZED OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS | HYBRIDON, INC. (US) | 1994-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020182602-A1 | Mobility-modified nucleobase polymers and methods of using same | PCNA, PNKP, SAMHD1 | CA2 2688/4885LMNA 1407/4885SLC34A1 591/4885 |
| US-20240209339-A1 | REDIRECTING RISC FOR RNA EDITING | ADAR, AGO2, METTL16 | CA2 4703/4885LMNA 874/4885SLC34A1 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.